The biological safety testing products and services market size was valued at USD 5.26 billion in 2025 and is projected to grow from USD 5.81 billion in 2026 to USD 13.09 billion by 2034 at a CAGR of 10.68% during the forecast period (2026-2034). North America dominated the biological safety testing products and services market with a market share of 42.5% in 2025.
Biological safety testing products and services include specialized solutions used to evaluate the safety, purity, potency, and quality of pharmaceuticals, biologics, vaccines, cell and gene therapies, and medical devices before commercialization. These products and services help detect contaminants, microorganisms, endotoxins, and other biological risks while ensuring compliance with regulatory standards. Demand is driven by the expanding biopharmaceutical industry, increasing biologics production, and stringent global quality and safety requirements.
Download a Free Sample To learn more about this report,
Growing Adoption of Advanced Safety Testing for Biologics and Cell Therapies
Biological Safety Testing Products and Services Market trends are being driven by the rapid growth of biologics, vaccines, biosimilars, and advanced cell and gene therapies. As pharmaceutical and biotechnology companies expand their development pipelines, the need for reliable sterility, endotoxin, mycoplasma, and viral safety testing has increased significantly. Regulatory agencies continue to emphasize stringent quality and safety standards before product approval, encouraging manufacturers to adopt validated testing solutions throughout the development and production process. These factors are supporting biological safety testing products and services market growth by increasing demand for comprehensive testing services and advanced analytical technologies.
Rising Investment in Rapid Microbial Detection and Automated Testing Solutions
Biological Safety Testing Products and Services Market trends are also being influenced by the increasing adoption of rapid microbial detection technologies and laboratory automation. Manufacturers are integrating automated testing platforms, molecular diagnostics, and digital laboratory workflows to improve testing accuracy, reduce turnaround times, and minimize manual errors. These innovations are helping laboratories process larger sample volumes while maintaining high quality standards and regulatory compliance. Such advancements are strengthening biological safety testing products and services market Share as pharmaceutical companies continue investing in efficient and scalable quality control processes.
Rising Biopharmaceutical Production and Stringent Regulatory Requirements
The biological safety testing products and services market is expanding steadily as the production of biologics, vaccines, cell and gene therapies, and biosimilars continues to increase worldwide. Regulatory agencies require comprehensive safety testing throughout the product development and manufacturing process to ensure the absence of microbial contamination, viruses, mycoplasma, and endotoxins. Growing investments in biologics manufacturing and stricter quality standards are strengthening biological safety testing products and services market demand, encouraging pharmaceutical and biotechnology companies to adopt advanced testing solutions.
High Testing Costs and Complex Regulatory Compliance
The biological safety testing products and services market faces restraints due to the high cost of advanced testing technologies and the complex regulatory requirements governing biologics manufacturing. Establishing compliant testing laboratories requires significant investment in specialized equipment, skilled personnel, and validated analytical methods. In addition, varying regulatory standards across different countries can increase operational complexity and extend product development timelines for manufacturers.
Expansion of Cell and Gene Therapies and Advanced Testing Technologies
The biological safety testing products and services market offers significant opportunities with the rapid growth of cell therapies, gene therapies, monoclonal antibodies, and other advanced biologics. These innovative therapies require highly sensitive biological safety testing throughout development and commercial production. Increasing adoption of rapid microbiological methods, automated testing platforms, and molecular diagnostic technologies is expected to strengthen biological safety testing products and services market share while reducing testing turnaround times and improving product quality.
Keeping Pace with Evolving Therapeutic Technologies and Quality Standards
The biological safety testing products and services market continues to face challenges as manufacturers must adapt to increasingly complex biologics and evolving regulatory expectations. Testing laboratories are required to validate new analytical methods, maintain data integrity, and deliver accurate results within shorter development timelines. At the same time, rising demand for advanced therapies places additional pressure on laboratory capacity, skilled professionals, and testing infrastructure. Meeting these requirements requires continuous investment in technology, workforce development, and quality management systems.
Request Customizationto receive a tailored report.
Reagents & Kits Segment Dominated the Market with 48.6% Share in 2025
The reagents & kits segment dominated the global biological safety testing products and services market with a 48.6% share in 2025, driven by their extensive use in routine quality control, contamination detection, and regulatory compliance testing during biopharmaceutical development and manufacturing. The growing production of biologics, vaccines, and cell-based therapies continues to support strong demand for reliable and standardized testing kits.
The services and instruments segments are witnessing steady growth as biopharmaceutical companies increasingly outsource biological safety testing while investing in advanced analytical equipment to improve testing accuracy and operational efficiency. Rising regulatory requirements and the need for faster product approvals continue to drive demand across both segments.
Continuous advancements in automated testing platforms, high-throughput screening technologies, and specialized laboratory services are expected to further strengthen market growth. Increasing investments in biologics manufacturing and quality assurance programs continue to create opportunities for both instruments and service providers.
Vaccines & Therapeutics Segment Dominated the Market with 44.2% Share in 2025
The vaccines & therapeutics segment dominated the global Biological Safety Testing Products and Services Market with a 44.2% share in 2025, supported by the increasing development of biologics, vaccines, and advanced therapeutic products requiring stringent safety evaluation. Growing regulatory oversight and the expansion of biopharmaceutical production continue to reinforce the segment's leading position.
The vaccines, monoclonal antibodies, recombinant protein, and blood & blood-based products segments are expanding steadily as manufacturers focus on ensuring product safety, purity, and consistency throughout the development and commercialization process. Increasing investments in immunotherapies, plasma-derived products, and recombinant biologics continue to drive testing demand across these applications.
The gene therapy, stem cell, and tissue & tissue-based products segments are witnessing rapid growth due to the rising adoption of regenerative medicine and next-generation cell and gene therapies. As these advanced therapies become more widely developed and commercialized, the need for comprehensive biological safety testing is expected to increase significantly.
Endotoxin Tests Segment Dominated the Market with 20.4% Share in 2025
The endotoxin tests segment dominated the global Biological Safety Testing Products and Services Market with a 20.4% share in 2025, driven by the critical need to detect bacterial endotoxins in biologics, vaccines, injectable drugs, and medical devices. Strict regulatory requirements and the importance of ensuring patient safety continue to support widespread adoption of endotoxin testing.
The sterility tests, cell line authentication & characterization tests, and adventitious agent detection tests are witnessing steady growth as manufacturers strengthen quality control processes and regulatory compliance. At the same time, bioburden tests and residual host contamination detection tests continue to gain importance in identifying microbial contamination and impurities during biologics manufacturing.
The others segment is also expanding steadily with the introduction of advanced biological safety assessment methods designed to address emerging therapeutic modalities. Continuous innovation in testing technologies, automation, and rapid detection platforms is expected to enhance efficiency and support growing demand across all test categories.
Speak to an Analystto discuss market opportunities.
North America biological safety testing products and services market accounted for 42.5% of the global market, reaching USD 2.24 billion in 2025, and is projected to grow at a CAGR of 12.4% during the forecast period. Strong biopharmaceutical manufacturing, increasing biologics and vaccine development, and strict regulatory requirements for product safety continue to drive regional market growth. Rising investments in quality assurance and laboratory testing services are also supporting market expansion.
The U.S. market was valued at USD 1.90 billion in 2025, making it the largest contributor in North America. Expanding biologics production, increasing clinical research activities, and growing demand for regulatory compliance testing continue to strengthen market growth.
Canada's market reached USD 0.34 billion in 2025. Rising investments in biotechnology research, expanding pharmaceutical manufacturing, and increasing adoption of advanced biological safety testing solutions continue to support steady market expansion.
Europe biological safety testing products and services market accounted for 28.3% of the global market, reaching USD 1.49 billion in 2025, and is expected to register a CAGR of 11.9% during the forecast period. Growing biologics production, increasing regulatory scrutiny, and rising investments in pharmaceutical quality control are driving regional growth. Expanding contract testing services are also contributing to market development.
Germany's market accounted for USD 0.43 billion in 2025. A strong pharmaceutical manufacturing base, increasing biologics development, and growing demand for high-quality laboratory testing continue to support market growth.
The UK market was valued at USD 0.30 billion in 2025. Rising investments in life sciences, expanding clinical research, and increasing outsourcing of biological safety testing continue to contribute to market expansion.
Asia Pacific biological safety testing products and services market accounted for 20.7% of the global market, valued at USD 1.09 billion in 2025, and is projected to register a CAGR of 14.6% during the forecast period. Expanding biopharmaceutical manufacturing, increasing vaccine production, growing biotechnology investments, and supportive government initiatives continue to accelerate regional market growth.
Japan's market generated USD 0.20 billion in 2025. Increasing biologics research, growing pharmaceutical innovation, and continuous investments in quality testing technologies continue to support market growth.
China's market accounted for USD 0.57 billion in 2025, representing the largest share within Asia Pacific. Rapid expansion of biopharmaceutical manufacturing, increasing clinical trials, and rising demand for regulatory testing services continue to drive market expansion.
Latin America biological safety testing products and services market accounted for 5.1% of the global market, reaching USD 0.27 billion in 2025, and is projected to grow at a CAGR of 11.2% during the forecast period. Growing pharmaceutical production, increasing healthcare investments, and rising demand for quality assurance services continue to support regional market growth.
Brazil's market reached USD 0.14 billion in 2025. Expanding pharmaceutical manufacturing, increasing biotechnology research, and growing adoption of biological safety testing services continue to create growth opportunities across the country.
Middle East & Africa biological safety testing products and services market accounted for 3.4% of the global market, totaling USD 0.18 billion in 2025, and is anticipated to grow at a CAGR of 10.7% during the forecast period. Increasing investments in pharmaceutical manufacturing, expanding healthcare infrastructure, and growing focus on product quality and regulatory compliance are supporting regional market growth.
The UAE market was valued at USD 0.06 billion in 2025. Rising investments in biotechnology, expanding pharmaceutical production capabilities, and increasing adoption of international quality standards continue to drive market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com